Two-stage sorting micro-fluidic chip for separating and detecting circulating tumor cells as well as preparation method and application of two-stage sorting micro-fluidic chip
By designing a two-stage sorting microfluidic chip, combining spiral chips and DLD chips, and combining HCR electrochemical signal amplification detection, the problem of low CTC separation purity in the existing technology is solved, and high throughput, high recovery rate and high CTC isolation and detection of purity are suitable for the early diagnosis and prognosis of circulating tumor cells.
Patent Information
- Application Number
- CN202411344061.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-25
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art When processing samples at high throughput, the isolation purity of circulating tumor cells (CTCs) is low, making it difficult to effectively isolate and detect. In particular, the technology based on a single helix chip has the disadvantage of the low purity of isolate CTCs.
Design a two-stage sorting microfluidic chip, combining a helical chip and a deterministic lateral displacement (DLD) chip, and adopts hybrid chain reaction (HCR) electrochemical signal amplification detection to achieve high throughput, high recovery rate and high purity CTC separation and detection.
It significantly improves the purity of CTC, breaks through the limitations of single sorting technology, realizes high-throughput sample processing and high-purity CTC separation, and the label-free separation strategy has little damage to CTC, which can obtain different subtypes of CTC and pass the electricity Chemical signals are sensitively detected.
Smart Images

Figure CN118956582A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of microfluidic equipment and circulating tumor cell detection, and in particular to a two-stage sorting microfluidic chip for separating and detecting circulating tumor cells, and a preparation method and application thereof. Background Art
[0002] CTCs are tumor cells that spontaneously fall off from the primary lesion and enter the peripheral blood circulation. They can escape the attack of the immune system and achieve rapid proliferation, thereby causing tumor metastasis and becoming tumor lesions visible to the naked eye. Therefore, the detection of CTCs is a "liquid biopsy" technology for solid tumors, providing a new option for real-time monitoring of cancer patients. CTCs are an extremely rare type of cell in the blood. Normal people contain 106 white blood cells and 109 red blood cells per milliliter of blood, while the CTC content is only 2-5, so the separation of CTCs from whole blood is crucial for subsequent detection and analysis. Therefore, it is urgent to develop a CTC effective separation and sensitive detection technology to provide new ideas for early diagnosis and prognosis of cancer based on CTCs. At present, CTC separation strategies can be divided into antigen-dependent separation and label-free separation (including cell size, deformability, density, etc.). CTC separation technology based on epithelial cell adhesion molecule (EpCAM) is the most commonly used typical antigen-dependent separation method, but it has problems such as no universal CTC antigen and the heterogeneity of antigens leading to the loss of CTC subtypes.
[0003] Label-free separation strategies may provide an attractive option for separating different subtypes of CTCs with minimal cell loss. Microfluidics technology, as an important strategy for label-free separation, distinguishes CTCs through the geometry of microfluidic channels and inherent hydrodynamics. For example, spiral chips have the characteristics of low cost, high throughput, and high recovery rate; deterministic lateral displacement (DLD) has high separation accuracy and has been widely used in the concentration and separation of biological particles such as white blood cells, stem cells, bacteria, exosomes, and DNA. However, a single separation technology has inherent limitations. For example, while spiral chips can process samples at high throughput, they inevitably have the disadvantage of low purity of isolated CTCs.
[0004] Chinese patent CN107084916A discloses a circulating tumor cell separation microfluidic chip device and its use method. Based on the differences in the nuclear-cytoplasmic ratio and surface charge between circulating tumor cells and blood cells, the invention uses fluid mechanics on a microfluidic chip to achieve non-antibody-dependent separation and enrichment of circulating tumor cells in samples, and achieves rapid high-throughput separation of circulating tumor cells that are non-antibody-dependent on tumor cells, with the advantages of simple operation and high degree of automation. However, the invention is still based on a single spiral chip to separate CTCs, and when processing samples at high throughput, it still has the disadvantage of low purity of separated CTCs.
[0005] Therefore, it is necessary to develop a two-stage sorting microfluidic chip for separating and detecting circulating tumor cells to solve the above problems. Summary of the invention
[0006] In view of the shortcomings in the prior art, the purpose of the present invention is to provide a two-stage sorting microfluidic chip for separating and detecting circulating tumor cells. The two-stage sorting microfluidic chip has the advantages of high-throughput sample processing, high recovery rate, and high-purity CTC separation. It is combined with hybridization chain reaction (HCR) electrochemical signal amplification detection, integrating separation and detection, and has the advantages of high sensitivity and low detection limit.
[0007] To achieve the above object, the present invention adopts the following technical solution: A two-stage sorting microfluidic chip for separating and detecting circulating tumor cells (CTCs), comprising a spiral chip and a deterministic lateral displacement (DLD) chip adapted to the spiral chip, wherein the spiral chip comprises two inlets, a 9 / 4 turn spiral channel and a Y-shaped outlet arranged at the end of the spiral channel, the two inlets comprising a PBS inlet close to the inner wall of the spiral and a sample inlet close to the outer wall of the spiral, and the Y-shaped outlet comprises a CTC collection liquid outlet and a waste liquid outlet; The DLD chip includes a chip substrate, a chip microcolumn array disposed on the chip substrate, a chip inlet connected to the CTC collection liquid outlet, and a chip outlet; Wherein, the inter-column gap of the DLD chip is 24-36 μm.
[0008] Furthermore, the spiral chip also includes a direct current channel arranged between the spiral channel and the Y-shaped outlet, the direct current channel is formed by extending the spiral channel along the tangential direction, the length of the direct current channel is 28 mm, the flow channel width of the CTC collection liquid outlet is 170 μm, and the flow channel width of the waste liquid outlet is 330 μm.
[0009] Preferably, the chip micro-column array is composed of a plurality of triangular micro-columns, and the gap between the columns is 32 μm.
[0010] The present invention provides a method for preparing the two-stage sorting microfluidic chip for separating and detecting CTCs as described above, comprising the following steps: S1. Design the spiral chip and DLD chip as described above; S2, setting the gaps between the chip micro-columns of the DLD chip to 24 μm, 28 μm, 32 μm, and 36 μm, respectively, performing simulations, optimizing the columnar morphology, and obtaining a design scheme for a two-stage sorting microfluidic chip; S3, according to the design scheme, using a soft lithography method to make a chip mold; S4. Perform hydrophobic treatment on the chip mold, mix the PDMS substrate and the curing agent in a ratio of 10:1 and remove bubbles, pour it on the chip mold, and cure it at 80°C overnight. Cut the PDMS template from the chip mold, remove the edge PDMS and perform drilling, and perform surface oxygen plasma treatment to tightly bond the glass slide and PDMS to form a closed chip.
[0011] Further, in step S2, the optimization simulation includes the following operations: based on the set gap values between multiple groups of chip micro-columns, the simulation software Fluent is used to use a discrete model to perform a two-dimensional coupling simulation of a bidirectional continuous phase and a discrete phase, wherein the flow field of the continuous phase is calculated using the Navier-Stokes equations, the fluid is incompressible, and the cells are treated as round spheres, and the deformation of the cells is not considered; an ultra-fine grid is used to divide the model to obtain a simulation model, and the triangular and circular micro-column morphologies are simulated respectively through the simulation model to optimize the columnar morphology.
[0012] Furthermore, in step S3, the chip mold is prepared using SU-8 2075 photoresist, the coating thickness of the photoresist is 150 μm, and the exposure energy of the UV lamp during the exposure process is 260 mJ / cm 2 .
[0013] The present invention also provides a method for separating and detecting CTCs using the two-stage sorting microfluidic chip as described above, comprising the following steps: S1. preparing a detection chip and a hybridization chain reaction (HDR) assembly, and connecting the inlet of the detection chip to the outlet of the two-stage sorting microfluidic chip to form a detection system, wherein the detection chip includes a glassy carbon electrode (GCE) and a CTC capture antibody immobilized on the glassy carbon electrode, and the HDR assembly includes three specific cancer aptamers and an electrochemical signal molecule; S2, a blood sample containing CTCs and a PBS buffer solution are introduced into the detection system at a flow rate ratio of 1:3, the blood sample passes through the two-stage sorting microfluidic chip and the detection chip in sequence, blood cells are trapped by the two-stage sorting microfluidic chip, more than 90% of CTCs enter the detection chip and are captured by the antibodies on the detection chip, PBS is introduced to wash the uncaptured CTCs, and a BSA solution is added to eliminate non-specific binding; S3. The HDR assembly is introduced into the detection chip, incubated for 1 h, and then washed for electrochemical detection. The electrochemical signal is used to detect and quantitatively analyze CTCs.
[0014] Furthermore, the method for preparing the detection chip is: after the bare glassy carbon electrode is electroplated with dopamine, it is further modified with streptavidin through an amidation reaction, and then Biotin-CD146 and Biotin-EpCAM are fixed on the surface of the glassy carbon electrode through the specific action of biotin and streptavidin SA to obtain the detection chip.
[0015] Furthermore, the HDR assembly is prepared by HCR assembly of a CTC detection aptamer and an electrochemical signal ferrocene.
[0016] Preferably, the electrochemical detection adopts pulse voltammetry DPV in PBS buffer solution, with a potential scanning range of -0.3-0.6 V, a pulse amplitude of 0.05 V, a pulse width of 0.05 s, and a pulse period of 0.2 s.
[0017] The beneficial effects of the present invention are: 1. The DLD chip designed and prepared by the present invention has the advantage of high sorting accuracy, can separate CTCs from most blood cells, and significantly improve the purity of CTCs.
[0018] 2. Compared with the traditional single sorting chip, the two-stage cell sorting microfluidic chip proposed in the present invention can break through the limitations of single sorting technology, combine the advantages of spiral chip and DLD chip, and simultaneously achieve high-throughput sample processing, high CTC recovery rate and high-purity CTC separation.
[0019] 3. The two-stage sorting chip proposed in the present invention is a label-free separation strategy, which causes little damage to CTCs, is independent of CTC surface antigens, and can obtain representative CTCs of different subtypes.
[0020] 4. Three specific cancer aptamers and electrochemical signal molecules were selected for HCR assembly to achieve the dual functions of specific recognition of CTCs and generation of electrical signals for sensitive detection of CTCs.
[0021] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention and implement it according to the contents of the specification, the following is a detailed description of the preferred embodiments of the present invention in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, some of the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0023] Figure 1 This is a schematic diagram of spiral and DLD two-stage chip separation of CTCs and HCR amplification signal detection of CTCs.
[0024] Figure 2 Figure 2 shows the flow behavior of 8-20 μm particles in chips with different inter-column gaps: (a) fluid flow behavior of G=24μm chip; (b) fluid flow behavior of G=28μm chip; (c) fluid flow behavior of G=32μm chip; (d) fluid flow behavior of G=36μm chip.
[0025] Figure 3 Figure 2 is the flow behavior of fluid in chips with different morphologies: (a) velocity vector diagram of chips with different morphologies; (b) velocity distribution diagram of chips with different morphologies.
[0026] Figure 4 Characterization of the sensing electrode and CTC detection: (a) HCR assembly principle; (b) PAGE diagram of MUC1 protein assembly; (c) optimization of CD146 and EpCAM capture antibody concentrations; (d) optimization of HCR assembly and CTC incubation time; (e) linear fitting of CTC concentration in whole blood and electrical signals. DETAILED DESCRIPTION
[0027] In order to better describe the present invention, the following is further illustrated by specific examples. The methods in the following examples are conventional methods unless otherwise specified.
[0028] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art; the reagents or materials described, unless otherwise specified, are all from commercial channels.
[0029] The present invention provides a two-stage sorting microfluidic chip for separating and detecting circulating tumor cells. The two-stage sorting microfluidic chip has the advantages of high-throughput sample processing, high recovery rate, and high-purity CTC separation. It is combined with hybridization chain reaction (HCR) electrochemical signal amplification detection, integrating separation and detection, and has the advantages of high sensitivity and low detection limit.
[0030] See also Figure 1The two-stage sorting microfluidic chip includes a spiral chip and a deterministic lateral displacement (DLD) chip adapted to the spiral chip. The spiral chip includes two inlets, a 9 / 4 turn spiral channel and a Y-shaped outlet arranged at the end of the spiral channel. The two inlets include a PBS inlet close to the inner wall of the spiral and a sample inlet close to the outer wall of the spiral. The Y-shaped outlet includes a CTC collection liquid outlet and a waste liquid outlet. A direct current channel is provided between the spiral channel and the Y-shaped outlet. The direct current channel is formed by extending the spiral channel along the tangential direction. The length of the direct current channel is 28 mm. The flow channel width of the CTC collection liquid outlet is 170 μm, and the flow channel width of the waste liquid outlet is 330 μm.
[0031] The DLD chip includes a chip substrate, a chip microcolumn array disposed on the chip substrate, a chip inlet connected to the CTC collection liquid outlet, and a chip outlet; the chip microcolumn array is composed of a number of triangular microcolumns, with a gap of 32 μm between columns, a critical radius Dc=10 μm, and a row transposition coefficient 𝜀=1 / 20. For the same sorting target, the critical radius of the triangle is smaller, and sorting can be performed with a smaller period and a larger gap size, which is conducive to improving throughput and reducing blockage, thereby enhancing sorting performance.
[0032] The inter-column gap of the DLD chip is 24~36μm, which meets the requirements of CTC purity in the sample liquid after sorting, can remove almost all white blood cells, and can effectively avoid the loss of CTCs.
[0033] The preparation method of the two-stage sorting microfluidic chip comprises the following steps: S1. Design the spiral chip and DLD chip as described above.
[0034] S2. Set the gaps between the micro-columns of the DLD chip to 24 μm, 28 μm, 32 μm, and 36 μm, respectively, perform simulations, optimize the columnar morphology, and obtain a design scheme for a two-stage sorting microfluidic chip; The specific steps of the optimization simulation are as follows: the simulation software Fluent is used to perform a two-dimensional coupling simulation of the bidirectional continuous phase and the discrete phase using a discrete model. The flow field of the continuous phase is calculated using the Navier-Stokes equations. The fluid is incompressible, and the cells are treated as round spheres without considering the deformation of the cells. The model is divided using an "ultra-fine" grid, and the total number of grids in the model is 84,680. The height of the first layer of the boundary layer is 0.0004 mm, the boundary layer expansion rate is 1.1, the boundary layer has 8 layers, and the overall grid is 0.004 mm. The fluid flow mode at the inlet is set to laminar flow, the inlet velocity is 30 mm / s (calculated based on the flow velocity of the spiral chip entering the DLD inlet), the outlet pressure is 0 pa, and the water density is 1000 kg / m 3 , hydrodynamic viscosity is 0.001Pa*s, particle density is 1050kg / m 3The release parameter of the particle is set to release one particle every 0.004 s. Based on the optimization gap in the previous step, the triangular and circular micro-column morphologies are simulated to optimize the columnar morphology.
[0035] S3. According to the above design scheme, a chip mold is made by soft lithography. The specific steps are as follows: clean and dry the silicon wafer, evenly coat the silicon wafer with a thickness of 150 μm SU-8 2075 photoresist at an initial speed of 500 r / min, 10 s and a final speed of 1600 r / min, 120 s, pre-bake the silicon wafer at 65°C for 10 min, then dry it at 95°C for 120 min until the edge is solidified, and expose the silicon wafer to ultraviolet light according to the above design scheme, with an exposure energy of 260 mJ / cm 2 After exposure, the wafer was baked at 65°C for 5 min and at 95°C for 12 min. After development with SU-8 developer for 30 min, the wafer was cleaned three times with isopropanol and dried at 115°C for 3 min to obtain a chip mold.
[0036] S4. Perform hydrophobic treatment on the chip mold, mix 20 g of PDMS substrate and curing agent in a ratio of 10:1 and remove bubbles, pour on the chip mold, cure at 80°C overnight, cut the PDMS template from the chip mold, remove the edge PDMS and perform drilling, and use surface oxygen plasma treatment to tightly bond the glass slide and PDMS to form a closed chip.
[0037] See also Figure 4 The above two-stage sorting microfluidic chip can be used to separate and detect CTCs. The separation and detection method includes the following steps: S1. Prepare a detection chip and an HDR assembly, and connect the inlet of the detection chip to the outlet of the two-stage sorting microfluidic chip to form a detection system. The detection chip includes a glassy carbon electrode (GCE) and a CTC capture antibody immobilized on the glassy carbon electrode. The HDR assembly includes three specific cancer aptamers and an electrochemical signaling molecule.
[0038] Specifically, the GCE electrode preparation steps are as follows: the GCE electrode is ultrasonically washed with distilled water and alcohol for 600 s in turn and dried at room temperature. Polydopamine (PDA) is dissolved in 20 mL PBS buffer (5.0 mmol / L). The electrode is placed in the PDA solution for electroplating to modify the surface with polymerized dopamine. The electrode is placed in a mixed solution of EDC and NHS and allowed to stand at room temperature for 10 min for amidation reaction (10 mg / mL EDC, 20 mg / mL NHS). 10μg / mL SA is modified in the working area of the electrode in a drip manner and coupled at room temperature for 1 h. Then, Botin-EpCAM and BotinCD146 antibodies are fixed on the electrode surface through interaction with SA. Finally, the antibody-modified electrode is inserted into the chip for capturing CTCs. The modification of the electrode in each step above is characterized by cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS), respectively. Among them, CV is in a buffer solution of 5 mmol / L [Fe(CN)6] 3- / 4- The EIS was carried out in 5 mmol / L [Fe(CN)6] 3- / 4- The scanning frequency was 0.19 kHz.
[0039] The HDR assembly was prepared by hybridization chain reaction assembly of CTC detection aptamers and electrochemical signal ferrocene, and CTC detection and quantitative analysis were performed through electrochemical signals. Taking the MUC1 assembly as an example, all aptamers were dissolved in PBS (final concentration of 100 μmol / L) after centrifugation, and equal volumes of DNA1 and H1 were mixed to form DNA1+H1; equal volumes of MUC1 and H2 were hybridized to form MUC1+H2; equal volumes of DNA1+H1 and MUC1+H2 were hybridized to form DNA1+H1 / MUC1+H2; equal volumes of initiator and DNA1+H1 / MUC1+H2 were mixed and incubated at room temperature for 24 h to form HCR assembly.
[0040] S2. CTCs of different concentrations were dissolved in 50-fold diluted healthy human blood samples (0, 10, 50, 100, 200 cells / mL), and introduced into the detection system with PBS buffer at a flow rate ratio of 1:3. The blood samples passed through the two-stage sorting microfluidic chip and the detection chip in turn. Blood cells were retained by the two-stage sorting microfluidic chip. More than 90% of CTCs entered the detection chip and were captured by the antibodies on the detection chip. PBS was passed to wash the uncaptured CTCs, and BSA solution was added to eliminate nonspecific binding.
[0041] S3. The HDR assembly was introduced into the detection chip, incubated for 1 h, then washed and electrochemically detected. The CTC was detected and quantitatively analyzed by electrochemical signals. The detection method used pulse voltammetry (DPV) in PBS buffer solution, with a potential scanning range of -0.3-0.6 V, a pulse amplitude of 0.05 V, a pulse width of 0.05 s, and a pulse period of 0.2 s.
[0042] Figure 1 The schematic diagram of the spiral chip and DLD chip two-stage chip separation of CTC and HCR amplification signal detection of CTC shown in the present invention: the first-stage spiral chip processes blood samples with high throughput, removes more than 95% of blood cells, and allows most CTCs to enter the next-stage chip; the second-stage DLD chip further removes blood cells with sizes similar to tumor cells, thereby improving the purity of CTCs. Finally, the three specific aptamers are hybridized with the electrochemical signal molecule ferrocene to perform HCR assembly, and the HCR assembly can both identify CTCs and generate electrical signals for CTC quantification.
[0043] The following is a further description of the preparation method of the two-stage sorting microfluidic chip for separating and detecting circulating tumor cells and the method of separating and detecting CTCs using the two-stage sorting microfluidic chip in conjunction with specific embodiments.
[0044] Example 1 Optimization of the gap between different columns of the chip For CTC sorting, the size of red blood cells in whole blood is 6-9.5 μm, the size of white blood cells is 7-10 μm, and the size of CTCs is 10-20 μm. In order to ensure a high blood cell removal rate and enable most CTCs to be sorted out, the DLD critical size is set to 10 μm. Through the formula calculation, it can be calculated that the inter-column gap G=30 μm. In order to study the specific effect of the gap G on the critical size of DLD, the inter-column gaps of the chip were set to 24 μm, 28 μm, 32 μm, and 36 μm respectively in the experiment. Simulated particles were taken from 8-20 μm (red blood cell size is 6-9.5 μm, white blood cell size is 7-10 μm, and CTC size is 10-20 μm) for DLD sorting tests. Figure 2 a is the sorting effect when the microcolumn gap G is 24 μm. Particles of 8 μm do not deviate (enlarged part), while particles larger than 9 μm deviate, indicating that the critical radius of the chip is larger than 8 μm and smaller than 9 μm, and it is difficult to remove white blood cells larger than 9 μm in the blood. Figure 2 b It can be seen that when G = 28 μm, the 9 μm particles are not offset, while the particles larger than 10 μm are offset, indicating that the critical radius of the chip is larger than 9 μm and smaller than 10 μm, and it is difficult to remove larger white blood cells in the blood. Figure 2c It can be seen that when G = 32 μm, the 10 μm particles have no deviation, while the particles larger than 11 μm have deviation, indicating that the critical radius of the chip is larger than 10 μm and smaller than 11 μm, which meets the requirement of improving the purity of CTCs in the sample liquid after spiral sorting and can almost remove all white blood cells. Figure 2 d shows that when G = 36 μm, 11 μm particles have no deviation, while particles larger than 12 μm have deviation, indicating that the critical radius of the chip is larger than 11 μm and smaller than 12 μm, which meets the requirement of improving the purity of CTCs in the sample liquid after spiral sorting and can remove almost all white blood cells, but may cause a small part of CTC loss. Therefore, G = 32 μm was selected as the inter-column gap.
[0045] Example 2 Optimization of different chip morphologies The critical radius (Dc) is not only affected by the gap size, but also by the microcolumn morphology. Currently, circular and triangular microcolumns are more commonly used, but some researchers have proposed that circular microcolumns will adsorb cells, causing fluid stagnation and chip clogging. Therefore, the present invention optimizes the morphology of array microcolumns by comparing the DLD sorting effects of circular and triangular microcolumns. By analyzing the flow velocity distribution in the gaps of circular and triangular microcolumns of the same size, such as Figure 3 As shown in a, the low-speed area in the gap of the circular micropillar is larger than that of the triangular micropillar, which will affect the zigzag motion of small particles and make them adsorb on the surface of the micropillar, causing fluid blockage. In addition, the flow velocity in the offset gap of the micropillar under the two morphologies is extracted, and the results are shown in Figure 3 As shown in b, the velocity distribution in the gap between the circular and triangular microcolumns is a symmetrical parabola. The velocity on both sides of the circle close to the microcolumn is lower than that of the triangle, and the peak velocity is higher than that of the triangle. The velocity distribution of the triangle is tilted to the left, where the velocity represents the first velocity, indicating that the fluid velocity close to the lower microcolumn is fast, the carrying flow is large, and Dc is small. Compared with the triangle, the critical radius of the circle is larger, and the particle size that can be sorted is similar to the gap size, which is prone to clogging. The above results show that for the same sorting target, the critical radius of the triangle is smaller, and sorting can be performed with a smaller period and a larger gap size, which is conducive to improving the flux and reducing clogging, and enhancing the sorting performance.
[0046] Example 3 Characterization of sensor electrodes and CTC detection In order to characterize the gradual modification process of the GCE electrode, the present invention uses CV and EIS for verification. Figure 4 As shown in a, the bare electrode is on [Fe(CN)6] 3- / 4-The solution has a good redox peak; after the bare electrode is electroplated with PDA, the current decreases because PDA wraps around the electrode surface and affects the transfer of electrons; after further modification with SA through an amidation reaction, the current further decreases and the peak becomes wider, because SA further hinders the transfer of electrons in the electrode; through the specific action of biotin and SA, Biotin-CD146 and Biotin-EpCAM are fixed on the electrode surface, resulting in a decrease in current, indicating the successful coupling of the antibody on its surface; when CTC is captured by the electrode, its current further decreases and the peak shifts to the left. Similarly, Figure 4 As shown in b, each step of electrode modification leads to a gradual increase in electrode resistance, indicating that the GCE electrode was successfully modified with antibodies and the sensing electrode was successfully prepared. The HCR assembly is assembled by three aptamers and the electrochemical signal molecule ferrocene (Fc). Taking MUC1 as an example, MUC1, H1, H2, DNA1, and initiator are assembled based on chain hybridization to form an HCR assembly in which multiple aptamers are bound to multiple Fcs. In order to verify the successful assembly of HCR, the present invention uses polyacrylamide gel electrophoresis (PAGE) to characterize it, and the results are shown in FIG. Figure 4 As shown in b. The nucleic acid with large molecular weight is slow, and the band is in the upper layer of the gel, while the small molecular weight is in the lower layer. From right to left, the bands are protein marker, DNA1 (16 bases), DNA1+H1 (63 bases), MUC1 (47 bases), MUC1+H2 (100 bases), DNA1+H1+MUC1+H2 (167 bases), initiator, and DNA1+H1+MUC1+H2+initiator (185 bases). By comparing with the protein marker, the position of the band is consistent with the theoretical DNA molecular weight. As the assembly proceeds, the DNA molecular weight continues to increase, the migration rate slows down, and it stays in the upper layer of the film. In order to obtain the best electrochemical detection results, the present invention optimizes the concentration of the capture antibody, the incubation time of the HCR assembly and the CTC. As Figure 4 As shown in Figure c, when the concentration of the two antibodies increased from 2 μmol / L to 6 μmol / L, the electrochemical signal continued to increase, and then changed slowly, with almost no signal increase. Therefore, the capture antibody concentration was selected to be 6 μmol / L. Figure 4 As shown in Figure d, when the incubation time of HCR and CTC is 30 min, it can specifically recognize the specific protein on the surface of CTC and generate electrical signals. Figure 4 As shown in Figure e, the CTC concentration is positively correlated with the electrical signal, and the linear relationship is good within the detection range of 0-200 cells / mL. The linear relationship is: y=0.0272x+2.6748 (R 2 =09523), LOD=11 cells / mL (S / N=3).
[0047] In summary, the DLD chip designed and prepared by the present invention has the advantage of high sorting accuracy, can separate CTCs from most blood cells, and significantly improve the purity of CTCs; compared with the traditional single sorting chip, the two-stage cell sorting microfluidic chip proposed in the present invention can break through the limitations of single sorting technology, combine the advantages of spiral chips and DLD chips, and simultaneously achieve high-throughput sample processing, high CTC recovery rate and high-purity CTC separation; the two-stage sorting chip proposed in the present invention is a label-free separation strategy, which has little damage to CTCs, does not rely on CTC surface antigens, and can obtain representative CTCs of different subtypes; three specific cancer aptamers and electrochemical signal molecules are selected for HCR assembly to achieve the dual functions of specific recognition of CTCs and generation of electrical signals for sensitive detection of CTCs.
[0048] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0049] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A two-stage sorting microfluidic chip for separating and detecting circulating tumor cells, characterized in that: It comprises a spiral chip and a deterministic lateral displacement chip adapted to the spiral chip, wherein the spiral chip comprises two inlets, a 9 / 4 turn spiral channel and a Y-shaped outlet arranged at the end of the spiral channel, the two inlets comprise a PBS inlet close to the inner wall of the spiral and a sample inlet close to the outer wall of the spiral, and the Y-shaped outlet comprises a CTC collection liquid outlet and a waste liquid outlet; The deterministic lateral displacement chip comprises a chip substrate, a chip microcolumn array disposed on the chip substrate, a chip inlet connected to the CTC collection liquid outlet, and a chip outlet; Wherein, the inter-column gap of the deterministic lateral displacement chip is 24~36μm.
2. The two-stage sorting microfluidic chip for separating and detecting circulating tumor cells according to claim 1, characterized in that: The spiral chip also includes a direct flow channel arranged between the spiral channel and the Y-shaped outlet. The direct flow channel is formed by extending the spiral channel along the tangential direction. The length of the direct flow channel is 28 mm. The flow channel width of the CTC collection liquid outlet is 170 μm, and the flow channel width of the waste liquid outlet is 330 μm.
3. The two-stage sorting microfluidic chip for separating and detecting circulating tumor cells according to claim 1, characterized in that: The chip micro-column array is composed of a plurality of triangular micro-columns, and the gap between the columns is 32 μm.
4. A method for preparing a two-stage sorting microfluidic chip for separating and detecting circulating tumor cells according to any one of claims 1 to 3, characterized in that: The steps include: S1. Designing a spiral chip and a deterministic lateral displacement chip as described in any one of claims 1 to 3; S2, setting the chip micro-column gaps of the deterministic lateral displacement chip to 24 μm, 28 μm, 32 μm, and 36 μm, respectively, performing simulations, optimizing the columnar morphology, and obtaining a design scheme for a two-stage sorting microfluidic chip; S3, according to the design scheme, using a soft lithography method to make a chip mold; S4. Perform hydrophobic treatment on the chip mold, mix the PDMS substrate and the curing agent in a ratio of 10:1 and remove bubbles, pour it on the chip mold, and cure it at 80°C overnight. Cut the PDMS template from the chip mold, remove the edge PDMS and perform drilling, and perform surface oxygen plasma treatment to tightly bond the glass slide and PDMS to form a closed chip.
5. The method for preparing a two-stage sorting microfluidic chip for separating and detecting circulating tumor cells according to claim 4, characterized in that: In step S2, the optimization simulation includes the following operations: based on the set gap values between multiple groups of chip micro-columns, the simulation software Fluent is used to use a discrete model to perform a two-dimensional coupling simulation of a bidirectional continuous phase and a discrete phase, wherein the flow field of the continuous phase is calculated using the Navier-Stokes equations, the fluid is incompressible, and the cells are treated as round spheres without considering the deformation of the cells; an ultra-fine grid is used to divide the model to obtain a simulation model, and the triangular and circular micro-column morphologies are simulated respectively by the simulation model to optimize the columnar morphology.
6. The method for preparing a two-stage sorting microfluidic chip for separating and detecting circulating tumor cells according to claim 4, characterized in that: In step S3, the chip mold is prepared using SU-8 2075 photoresist, the coating thickness of the photoresist is 150 μm, and the exposure energy of the UV lamp during the exposure process is 260 mJ / cm 2 .
7. A method for separating and detecting circulating tumor cells using the two-stage sorting microfluidic chip according to any one of claims 1 to 3, characterized in that: The steps include: S1. Prepare a detection chip and a hybridization chain reaction assembly, and connect the inlet of the detection chip to the outlet of the two-stage sorting microfluidic chip to form a detection system, wherein the detection chip includes a glassy carbon electrode and a circulating tumor cell capture antibody fixed on the glassy carbon electrode, and the hybridization chain reaction assembly includes three specific cancer aptamers and an electrochemical signal molecule; S2, passing a blood sample containing circulating tumor cells and a PBS buffer into the detection system at a flow rate ratio of 1:3, the blood sample passes through a two-stage sorting microfluidic chip and a detection chip in sequence, the blood cells are intercepted by the two-stage sorting microfluidic chip, more than 95% of the circulating tumor cells enter the detection chip and are captured by the antibodies on the detection chip, PBS is passed to wash the circulating tumor cells that are not captured, and a BSA solution is added to eliminate non-specific binding; S3. The hybridization chain reaction assembly is introduced into the detection chip, incubated for 1 hour, and then washed for electrochemical detection. The circulating tumor cells are detected and quantitatively analyzed through the electrochemical signal.
8. The method for separating and detecting circulating tumor cells using a two-stage sorting microfluidic chip as claimed in claim 7, characterized in that: The method for preparing the detection chip is as follows: after the bare glassy carbon electrode is electroplated with dopamine, it is further modified with streptavidin through an amidation reaction, and then Biotin-CD146 and Biotin-EpCAM are fixed on the surface of the glassy carbon electrode through the specific action of biotin and streptavidin SA to obtain the detection chip.
9. The method for separating and detecting circulating tumor cells using a two-stage sorting microfluidic chip as claimed in claim 7, characterized in that: The hybridization chain reaction assembly is prepared by hybridization chain reaction HCR assembly of circulating tumor cell detection aptamer and electrochemical signal ferrocene.
10. The method for separating and detecting circulating tumor cells using a two-stage sorting microfluidic chip as claimed in claim 7, characterized in that: The electrochemical detection adopts pulse voltammetry DPV in PBS buffer solution, with a potential scanning range of -0.3-0.6 V, a pulse amplitude of 0.05 V, a pulse width of 0.05 s, and a pulse period of 0.2 s.
Citation Information
Cited By
Particle sorting system, using method and chip
CN121347331A
